The F18-FDG PET/CT imaging method may also contribute to the follow up of granulomatous and inflammatory diseases.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:A 19-year-old woman with a history of tuberculosis (TB) in her family presented to theinfectious disease clinic of our hospital with right flank pain, nausea, vomiting, a 10- kg weight loss, and decreased urine volume for the past two months.
📊
Key Findings & Data:Empirical anti-TBtreatment was initiated due to her family history of tuberculosis, a positive purified proteinderivative skin test, and the presence of a nodule in the posterobasal segment of the lungupon F18-FDG PET/CT.
💡
Conclusion & Impact:The F18-FDG PET/CT imaging method may also contribute to the follow up of granulomatous and inflammatory diseases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
A 19-year-old woman with a history of tuberculosis (TB) in her family presented to theinfectious disease clinic of our hospital with right flank pain, nausea, vomiting, a 10- kg weight loss, and decreased urine volume for the past two months. Empirical anti-TBtreatment was initiated due to her family history of tuberculosis, a positive purified proteinderivative skin test, and the presence of a nodule in the posterobasal segment of the lungupon F18-FDG PET/CT. We aimed to present the complete regression of a pelvic mass lesionafter empirical tuberculosis treatment that was visualized on follow-up F18-FDG PET/CTimaging and discuss its contribution to the literature. F18-FDG PET/CT imaging follow up may offer an invaluable resource for monitoring extrapulmonary involvement of TB infected patients. The F18-FDG PET/CT imaging method may also contribute to the follow up of granulomatous and inflammatory diseases.
🔖
Cite This Article
TATOĞLU, M. T., AKBULUT, E., ARSLAN, F. (2022). Complete Pelvic Mass Regression FollowingTuberculosis Treatment as Indicated byF18-FDG PET/CT. Infectious diseases and clinical microbiology (Online), Cilt: 2 - Sayı: 3, 175–178. https://ajindex.com/articles/539114
1 Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013; 368: 745–55. 2 Coleman MT, Maiello P, Tomko J, Frye LJ, Fillmore D, Janssen C, et al. Early changes by 18Fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun 2014; 82: 2400–4. 3 Ganchua SKC, Cadena AM, Maiello P, Gideon HP, Myers AJ, Junecko BF, et al. Lymph nodes are sites of prolonged bacterial persistence during Mycobacterium tuberculosis infection in macaques. PLoS Pathog 2018; 14: e1007337. 4 Dureja S, Sen IB, Acharya S. Potential role of F18 FDG PET-CT as an imaging biomarker for the noninvasive evaluation in uncomplicated skeletal tuberculosis: a prospective clinical observational study. Eur Spine J 2014; 23: 2449–54. 5 Shejul Y, Chhajed PN, Basu S. 18F-FDG PET and PET/CT in diagnosis and treatment monitoring of pyrexia of unknown origin due to tuberculosis with prominent hepatosplenic involvement. J Nucl Med Technol. 2014; 42: 235–7. 6 Malherbe ST, Shenai S, Ronacher K, Loxton AG, Dolganov G, Kriel M, et al. Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure. Nat Med 2016; 22: 1094–100. 7 Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Executive summary: Official American Thoracic Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016; 1; 63: 853–67. 8 Rabahi MF, Rodrigues da Silva JL, Ferreira ACG, Tannus-Silva DGS, Conde MB. Tuberculosis treatment. J Bras Pneumol 2017; 43: 472–86.